Skip to main content

Cipla scores a generic win over Roche

Cipla wins over Roche
NEW DELHI: In what could be a shot in the arm for Indian generic drug makers, the Delhi High Court on Wednesday rejected an injunction plea by Swiss drug major Roche to prevent Cipla from manufacturing and selling generic versions of its patented anti-cancer drug Tarceva (Erlotinib) in India.

The Indian drug maker's generic version of Tarceva is priced at one-third the price of Tarceva and the HC rejected Roche appeal in public interest given the huge cost difference between the two drugs.

However, this is only an interim order and HC will deliver its final judgement at the completion of the hearing. The court has also directed Cipla to keep a separate record of the sale of its generic anti-cancer drug as it will have to compensate Roche if the final verdict goes in favour of the Swiss company.

"Roche has applied for a stay (on the sale of the generic version of Tarceva). This is an interim order for not granting the stay," said Cipla joint MD Amar Lulla.

"The court has given an interim order which allows Cipla to market the generic copy of Tarceva. However, Cipla has been asked to keep the sales record of Tarceva separately, as Cipla would have to pay profit and damages cost to Roche if the Swiss company gets a favourable verdict after the complete hearing," an executive of an Indian drug maker who attended the hearing told ET.

Cipla's share closed at Rs 206 on BSE, up 0.76% from Tuesday's close of Rs 204.45. Roche received patent for Tarceva in India last year, but has been subsequently facing post-grant patent opposition from Cipla and NGOs. Two months ago Cipla decided to market copy cat versions of the drug in India at Rs 1,600 per tablet one-third the cost of the patented drug.

India, with a strong generic drug industry is fast becoming a battle ground between domestic drug makers and big pharma MNCs. With the Indian pharma industry set to grow annually at 13%, drug discovery companies are keen to establish a strong presence in India and protect their patents here.

Domestic drug makers, on the other hand, want a liberal interpretation of the Indian patent laws and any favourable verdict strengthens their case. Watching closely from the sidelines are consumers who stand to gain if generic versions are introduced at lower costs.

In addition, there are concerns in the government that once drugs are patented, the cost of medical treatment could become unaffordable and will prevent many patients from getting treatment of diseases such as HIV and cancer.

Several Indian companies and NGOs have filed both pre-patent and post-patent oppositions to prevent global companies from getting patent protection. In the much publicised Glivec case, Novartis had unsuccessfully challenged section 3(d) of the Indian patent law which states that an innovation to a drug can only be granted patent if the new drug provides significant therapeutic advantages.

This decision had made Indian patent laws one of the most effective in the world. Another Indian drug maker, Hyderabad-based Natco has also sought compulsory licensing (CL) from the government for two cancer drugs Tarceva and Pfizer's Sunitnib (Sutent). However, the decision on Cipla's case is not expected to have any bearing on Natco's plea for a CL.

Popular posts from this blog

Bio-fuel has top investors powered up

23RD ,JUNE India's fortune-hunters believe their new-found love for biofuel will pay off. India's well-known investors who are known for their Midas touch have spotted an opportunity in bio-fuel, betting big on ethanol, bio-mass and even bio-fuel equipment makers in India and other parts of the globe. Billionaires Rakesh Jhunjhunwala, C Sivasankaran, Vinod Khosla, founder of Sun Microsystems, and Nemish Shah, the media-shy joint partner of Enam Financial Services, are investing in bio-fuel makers quietly, expecting that bio-fuel will have a big play in the coming years as the world looks for a viable alternative to the fast depleting oil reserves. Jhunjhunwala, who is known for his ability to spot a multi-bagger at a very early stage, recently invested in Hyderabad-based bio-fuel firm Nandan Biometrics.He is also a 10 per cent stakeholder in Praj Industries, which is a bio-fuel technology provider…

up to 8,500% return in 5 years! Investors made a killing in these 30 smallcap stocks

U By Rahul Oberoi, | Updated: Dec 01, 2017, 04.06 PM IST Post a Comment
Efficiency pays in the long run. Among the top smallcap plays on Dalal Street, 30 companies with stable return on equity (RoE) and return on capital employed (RoCE) have surged up to 8,500 per cent over the past five years.

All these companies had a debt-to-equity ratio of less than 1 and have been maintaining RoE and RoCE of over 20 per cent since 2012-13.

Avanti Feeds emerged the chart topper, with an 8,527 per cent gain to Rs 2,596.60 as of November 28 from Rs 30.10 ..

ovember 28 from Rs 30.10 on November 27, 2012. The company’s return on equity for FY17, FY16, FY15, FY14 and FY13 stood at 42.65 per cent, 46.21 per cent, 52.41 per cent, 45.79 per cent and 27.60 per cent, respectively. Avanti also managed to achieve a return on capital employed of over 50 per cent in last four years. Its RoCE stood at 28.59 per cent inRoE measures net income earned for every rupee of shareholder funds, while…

5 dark-horse picks

Kwadrat/ Kwadrat/
If you are a conservative investor, using the mutual fund route is the best way to invest in stocks. But if you are game for some excitement, you might want to dabble directly in stocks, especially small-cap stocks. Stocks that are smaller in size, in terms of market capitalisation, carry higher risk. The reasons are — one, lower traded volume increases price volatility, two, information is usually scarce on these companies, three, business risk is higher since many of these companies are dependent on a single product and four, governance risk is also higher in these stocks. That said, small-cap stocks have the capacity to deliver far greater returns when compared to large-cap stocks. Sample this: there were 16 stocks with market cap more than ₹50,000 crore in January 2009. These stocks delivered an average return of 138 per cent in the last eight years but 4 out of every 10 stocks in this group delivered negative returns. On the ot…